Testing effectiveness (Phase 2)Ended earlyNCT01331824
What this trial is testing
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Who this might be right for
Bladder Cancer
Matthew Galsky 22